The MS Academy will hold a live webinar via Zoom at 12:00 on Tuesday, 31 March 2020 for an interactive debate with Prof Klaus Schmierer and Prof David Baker around COVID-19. You are invited to join the video conference from your computer, tablet or phone. The webinar will be live for 60 mins and a recording will be available following the meeting.
Should ocrelizumab and cladribine be treated in the same way as alemtuzumab in terms of risk of COVID-19? Join the debate tomorrow with Prof’s Klaus Schmierer & David Baker, Barts and The London School of Medicine and Dentistry https://t.co/h5aVmi6QiW @ACNRjournal @TheUKMSSNA
— Neurology Academy (@TheNeuroAcademy) March 30, 2020
Prof Klaus Schmierer, Professor of Neurology, Barts and The London School of Medicine and Dentistry
Prof David Baker, Professor of Neuroimmunology, Barts and The London School of Medicine and Dentistry
For more webinars visit: multiplesclerosisacademy.org/covid-19
This meeting has been sponsored by Roche Products Limited. Roche Products Limited has had no control over the educational content of this activity.